7-T Neuromelanin and R2* MRI in Parkinson Disease

Related Articles:

• 7-T Neuromelanin and R2* MRI in Parkinson Disease August 2, 2022 Radiology. 2022 Aug 2:220230. doi: 10.1148/radiol.220230. Online ahead of print.NO ABSTRACTPMID:35916676 | DOI:10.1148/radiol.220230
• 7-T Neuromelanin and R2* MRI in Parkinson Disease August 2, 2022 Radiology. 2022 Aug 2:220230. doi: 10.1148/radiol.220230. Online ahead of print.NO ABSTRACTPMID:35916676 | DOI:10.1148/radiol.220230
• 7-T Neuromelanin and R2* MRI in Parkinson Disease August 2, 2022 Radiology. 2022 Aug 2:220230. doi: 10.1148/radiol.220230. Online ahead of print.NO ABSTRACTPMID:35916676 | DOI:10.1148/radiol.220230
• 7-T Neuromelanin and R2* MRI in Parkinson Disease August 2, 2022 Radiology. 2022 Aug 2:220230. doi: 10.1148/radiol.220230. Online ahead of print.NO ABSTRACTPMID:35916676 | DOI:10.1148/radiol.220230
• The “Black Stuff” and Parkinson’s Disease November 23, 2020 It’s been more than a 100 years since Konstantin Tretiakoff, a doctoral student at the Salpêtrière Hospital in Paris, reported for the first time in his remarkable PhD thesis (1919) the presence of a marked loss of pigmented neurons in the substantia nigra, visible with the naked eye, in the brains of patients with Parkinson’s disease (PD). While this finding…
• The “Black Stuff” and Parkinson’s Disease November 23, 2020 It’s been more than a 100 years since Konstantin Tretiakoff, a doctoral student at the Salpêtrière Hospital in Paris, reported for the first time in his remarkable PhD thesis (1919) the presence of a marked loss of pigmented neurons in the substantia nigra, visible with the naked eye, in the brains of patients with Parkinson’s disease (PD). While this finding…
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease. June 30, 2019 Related ArticlesNeuromelanin, aging, and neuronal vulnerability in Parkinson's disease. Mov Disord. 2019 Jun 28;: Authors: Vila M Abstract Neuromelanin, a dark brown intracellular pigment, has long been associated with Parkinson's disease (PD). In PD, neuromelanin-containing neurons preferentially degenerate, tell-tale neuropathological inclusions form in close association with this pigment, and neuroinflammation is restricted to neuromelanin-containing areas. In humans, neuromelanin accumulates with…
• Neuromelanin modulates heterocyclic aromatic amine-induced dopaminergic neurotoxicity. September 29, 2019 Neuromelanin modulates heterocyclic aromatic amine-induced dopaminergic neurotoxicity. Toxicol Sci. 2019 Sep 28;: Authors: Lawana V, Um SY, Rochet JC, Turesky RJ, Shannahan JH, Cannon JR Abstract Heterocyclic aromatic amines (HAAs) are mutagens and potential human carcinogens. Our group and others have demonstrated that HAAs may also produce selective dopaminergic neurotoxicity, potentially relevant to Parkinson's disease (PD). The goal of this…
• Distinctly human: Kangaroos November 15, 2019   It is often said that only humans develop Parkinson’s. It is a distinctly human condiiton, and this is true (at the time of publishing this post). But there are interesting Parkinson’s-related observations in the animal world that could tell us something about this ‘very human’ condition. We have previously highlighted reports of this nature (Click here for an example).…
• Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes June 8, 2021 Radiology. 2021 Jun 8:203341. doi: 10.1148/radiol.2021203341. Online ahead of print.ABSTRACTParkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the midbrain. There are various imaging markers for Parkinson disease. Recent advances in MRI have enabled elucidation of the underlying pathophysiologic changes in the nigral structure. This has contributed to accurate and early diagnosis and has improved disease…
• Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes June 8, 2021 Radiology. 2021 Jun 8:203341. doi: 10.1148/radiol.2021203341. Online ahead of print.ABSTRACTParkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the midbrain. There are various imaging markers for Parkinson disease. Recent advances in MRI have enabled elucidation of the underlying pathophysiologic changes in the nigral structure. This has contributed to accurate and early diagnosis and has improved disease…
• Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes June 8, 2021 Radiology. 2021 Jun 8:203341. doi: 10.1148/radiol.2021203341. Online ahead of print.ABSTRACTParkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the midbrain. There are various imaging markers for Parkinson disease. Recent advances in MRI have enabled elucidation of the underlying pathophysiologic changes in the nigral structure. This has contributed to accurate and early diagnosis and has improved disease…
• Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes June 8, 2021 Radiology. 2021 Jun 8:203341. doi: 10.1148/radiol.2021203341. Online ahead of print.ABSTRACTParkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the midbrain. There are various imaging markers for Parkinson disease. Recent advances in MRI have enabled elucidation of the underlying pathophysiologic changes in the nigral structure. This has contributed to accurate and early diagnosis and has improved disease…
• Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra October 5, 2021 Radiology. 2021 Oct 5:210116. doi: 10.1148/radiol.2021210116. Online ahead of print.ABSTRACTBackground The heterogeneous composition of substantia nigra (SN), including iron, nigrosome-1 substructure, and myelinated white matter, complicates the interpretation of MRI signals. Purpose To investigate R2* and quantitative susceptibility mapping (QSM) in the SN subdivisions of participants with Parkinson disease and healthy control subjects. Materials and Methods In this prospective study…
• Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra October 5, 2021 Radiology. 2021 Oct 5:210116. doi: 10.1148/radiol.2021210116. Online ahead of print.ABSTRACTBackground The heterogeneous composition of substantia nigra (SN), including iron, nigrosome-1 substructure, and myelinated white matter, complicates the interpretation of MRI signals. Purpose To investigate R2* and quantitative susceptibility mapping (QSM) in the SN subdivisions of participants with Parkinson disease and healthy control subjects. Materials and Methods In this prospective study…
• Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra October 5, 2021 Radiology. 2021 Oct 5:210116. doi: 10.1148/radiol.2021210116. Online ahead of print.ABSTRACTBackground The heterogeneous composition of substantia nigra (SN), including iron, nigrosome-1 substructure, and myelinated white matter, complicates the interpretation of MRI signals. Purpose To investigate R2* and quantitative susceptibility mapping (QSM) in the SN subdivisions of participants with Parkinson disease and healthy control subjects. Materials and Methods In this prospective study…
• Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra October 5, 2021 Radiology. 2021 Oct 5:210116. doi: 10.1148/radiol.2021210116. Online ahead of print.ABSTRACTBackground The heterogeneous composition of substantia nigra (SN), including iron, nigrosome-1 substructure, and myelinated white matter, complicates the interpretation of MRI signals. Purpose To investigate R2* and quantitative susceptibility mapping (QSM) in the SN subdivisions of participants with Parkinson disease and healthy control subjects. Materials and Methods In this prospective study…
• Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra October 5, 2021 Radiology. 2021 Oct 5:210116. doi: 10.1148/radiol.2021210116. Online ahead of print.ABSTRACTBackground The heterogeneous composition of substantia nigra (SN), including iron, nigrosome-1 substructure, and myelinated white matter, complicates the interpretation of MRI signals. Purpose To investigate R2* and quantitative susceptibility mapping (QSM) in the SN subdivisions of participants with Parkinson disease and healthy control subjects. Materials and Methods In this prospective study…
• Cortical Thickness from MRI to Predict Conversion from Mild Cognitive Impairment to Dementia in Parkinson Disease: A Machine Learning-based Model May 25, 2021 Radiology. 2021 May 25:203383. doi: 10.1148/radiol.2021203383. Online ahead of print.ABSTRACTBackground Group comparison results associating cortical thinning and Parkinson disease (PD) dementia (PDD) are limited in their application to clinical settings. Purpose To investigate whether cortical thickness from MRI can help predict conversion from mild cognitive impairment (MCI) to dementia in PD at an individual level using a machine learning-based model.…
• Cortical Thickness from MRI to Predict Conversion from Mild Cognitive Impairment to Dementia in Parkinson Disease: A Machine Learning-based Model May 25, 2021 Radiology. 2021 May 25:203383. doi: 10.1148/radiol.2021203383. Online ahead of print.ABSTRACTBackground Group comparison results associating cortical thinning and Parkinson disease (PD) dementia (PDD) are limited in their application to clinical settings. Purpose To investigate whether cortical thickness from MRI can help predict conversion from mild cognitive impairment (MCI) to dementia in PD at an individual level using a machine learning-based model.…
• Cortical Thickness from MRI to Predict Conversion from Mild Cognitive Impairment to Dementia in Parkinson Disease: A Machine Learning-based Model May 25, 2021 Radiology. 2021 May 25:203383. doi: 10.1148/radiol.2021203383. Online ahead of print.ABSTRACTBackground Group comparison results associating cortical thinning and Parkinson disease (PD) dementia (PDD) are limited in their application to clinical settings. Purpose To investigate whether cortical thickness from MRI can help predict conversion from mild cognitive impairment (MCI) to dementia in PD at an individual level using a machine learning-based model.…